Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2025, for Mainz Biomed N.V. (trading as Quantum Cyber N.V., ticker: QUCY). The company historically developed in-vitro diagnostic (IVD) tests for cancer detection. In early 2026, the Board executed a strategic pivot: it wound down its colorectal cancer business (ColoAlert and next-generation CRC products) to focus exclusively on a blood-based pancreatic cancer detection test and a new post-quantum cybersecurity initiative. Consequently, the company changed its name to Quantum Cyber N.V. and appointed new leadership, including David Lazar as Co-CEO and Robert Liscouski as Non-Executive Chairman.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $537,080 | $893,991 |
| Gross Profit | $389,792 | $574,883 |
| Gross Margin | 73% | 64% |
| Net Loss | $(16,210,718) | $(21,598,772) |
| Operating Cash Flow | $(10,979,587) | $(17,329,254) |
| Cash and Equivalents (Year End) | $889,091 | $6,235,670 |
| Working Capital Deficit | $(1.9 million) | Not explicitly stated |
| Accumulated Deficit | $(104.9 million) | $(88.7 million) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 40% to $537,080, driven by the wind-down of direct-to-consumer sales in 2024 to focus on lab partner sales.
- Impairment Loss: The company recorded a non-cash impairment loss of $2,640,280 on ColoAlert intellectual property due to the decision to cease development and sell the assets.
- Expense Reduction: Total operating expenses decreased 15% to $16.5 million. Sales and marketing expenses dropped 42% due to reduced advertising and labor costs. R&D expenses decreased 15% despite increased clinical study costs, offset by a 65% reduction in personnel.
- Debt Reduction: Convertible debt balances were substantially reduced in 2025, leading to a significant decrease in fair value adjustments and interest expense compared to 2024.
- Accounting Transition: The company ceased to qualify as a Foreign Private Issuer as of January 1, 2026, and retroactively converted financial statements from IFRS to U.S. GAAP.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy: Management plans to fund operations through current cash, a recent $6 million preferred stock offering (closed in early 2026), and an Equity Distribution Agreement. The primary focus is the commercialization of the pancreatic cancer test and the expansion into post-quantum cybersecurity.
Going Concern: The filing includes a "Substantial Doubt" opinion from auditors regarding the company's ability to continue as a going concern due to recurring losses, negative working capital, and reliance on future financing.
Unusual Items and Risks:
- Nasdaq Compliance: The company received a notice of deficiency for failing to meet the $1.00 minimum bid price requirement. It has 180 days to regain compliance, potentially via a reverse stock split.
- Control Change: A Securities Purchase Agreement with David Lazar involves the issuance of preferred shares convertible into over 95% of the company's outstanding ordinary shares upon full conversion, subject to shareholder approval.
- Internal Controls: Management identified material weaknesses in internal control over financial reporting, including lack of written policies, inadequate documentation, and insufficient segregation of duties.
- Legal Proceedings: A dispute with Boustead Securities is ongoing, though no pending claims currently exist against the company.
Investor Verification Checklist
- Financing Success: Verify the closing of the $6 million Lazar investment and the outcome of the shareholder vote required for the conversion of preferred shares.
- Nasdaq Status: Monitor the company's ability to regain compliance with Nasdaq listing rules (minimum bid price) by September 16, 2026.
- Asset Sales: Confirm the finalization of the ColoAlert intellectual property sale and the proceeds received.
- Going Concern: Assess the sufficiency of the $889,091 cash balance plus new financing to cover the projected burn rate for the next 12 months.
- Internal Controls: Review the remediation plan for material weaknesses in financial reporting controls to ensure future financial statement reliability.